ANI Pharmaceuticals Inc. (ANIP)
69.21
0.01 (0.01%)
At close: Apr 17, 2025, 3:59 PM
70.08
1.26%
After-hours: Apr 17, 2025, 06:14 PM EDT
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations.
The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations.
The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals Inc.

Country | United States |
IPO Date | May 5, 2000 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 897 |
CEO | Nikhil Lalwani |
Contact Details
Address: 210 Main Street West Baudette, Minnesota United States | |
Website | https://www.anipharmaceuticals.com |
Stock Details
Ticker Symbol | ANIP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001023024 |
CUSIP Number | 00182C103 |
ISIN Number | US00182C1036 |
Employer ID | 58-2301143 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nikhil Lalwani | President, Chief Executive Officer & Director |
Muthusamy Shanmugam MS R.Ph. | Head of R&D, Chief Operating Officer of New Jersey Operations & Director |
Stephen P. Carey | Senior Vice President of Finance & Chief Financial Officer |
Christopher K. Mutz | Senior Vice President & Head of Rare Disease |
Dr. Mary Pao M.D., Ph.D. | Chief Medical Officer |
Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease |
Krista L. Davis | Senior Vice President & Chief Human Resources Officer |
Ori Gutwerg | Senior Vice President of Generics |
Thomas Andrew Rowland | Senior Vice President & Head of Established Brands |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 14, 2025 | 4 | Filing |
Apr 10, 2025 | ARS | Filing |
Apr 10, 2025 | DEFA14A | Filing |
Apr 10, 2025 | DEF 14A | Filing |
Apr 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Mar 31, 2025 | PRE 14A | Filing |
Mar 25, 2025 | 4 | Filing |
Mar 25, 2025 | 4 | Filing |
Mar 20, 2025 | 4 | Filing |
Mar 18, 2025 | 8-K | Current Report |